Floatz logo

Abemaciclib

DILI

University of Milano BicoccaSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the DILI cohort.

Asset / SponsorPhaseRating
URSODEOXYCHOLIC ACID
Taipei Veterans General Hospital, Taiwan
Phase 4BB
Levocarnitine
Children's Hospital of Orange County
Early Phase 1C
Palbociclib
University of Milano Bicocca
D
Ribociclib
University of Milano Bicocca
D
Silymarin
Tanta University
Phase 2/3NR
mt2004
Xi'An Aolitai Pharmaceutical Technology Co Ltd
Phase 2NR

Same molecule, other indications

Abemaciclib is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Hormone Receptor Positive TumorDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →